A Phase 2 interventional study of Florbetaben (BAY94-9172) in Down Syndrome and Amyloid Beta-protein, sponsored by Life Molecular Imaging SA. Completed at 2 sites in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-05.
Sponsored by Life Molecular Imaging SA (part of Lantheus Holdings, Inc.) · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Down Syndrome with a site in United States — 48 open to participants now, 56 under way, 4 of them phase 3. Down Syndrome · United States.
Among the 205 studies in Down Syndrome with a site in United States, this one is the 29th largest by enrollment of the 131 interventional ones that give a count, is one of 11 that started in 2009, is one of 23 in phase 2, and was the 21st registered.
439 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.
Browse Down Syndrome studies →48 of the 205 studies in Down Syndrome with a site in United States are open now. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in United States, Spain
Ages 40–55
Ohio State University · Sites in United States
Ages 5–12
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1–120 · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 6–22
RTI International · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 58 (77%) stop at 75 or younger; 61 take children under 18; 19 take healthy volunteers.
This study: 21 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 26 · Phase 3 10 · Phase 4 5
First in 1981; this study’s year is marked. 11 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is above the median of 38 across 287 interventional studies indexed under Down Syndrome.
Median enrollment 40 across the 131 interventional studies, 433 across the 74 observational. Of the 139 that completed or were terminated, 42 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 205 have an industry lead sponsor. The 10 most frequent:
This study is registered under Life Molecular Imaging SA, one of the names counted as Lantheus Holdings, Inc.. Under that name alone:
Life Molecular Imaging SA is the lead sponsor of 8 studies on the registry; none are open to participants now.
Lantheus Holdings, Inc. has 1 study filed under Down Syndrome — fewer than ten, so there is no comparison to draw.
14 of the studies in Down Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03914625Phase 3National Cancer Institute (NCI)A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | 2027-09-30 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07008989Boston CollegeA VIRTUAL Three-month Intervention Study of the Effects of a Smartphone Application (HippoCamera) on Memory in Teens and Young Adults With Down Syndrome | 2026-12-31 |
| NCT05196984Massachusetts Institute of TechnologyGamma Frequency Stimulation in Individuals With Down Syndrome | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 205 studies in Down Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals without DS. Given that individuals with Down Syndrome develop β-amyloid pathology over the age of 40, the clinical diagnosis of Down Syndrome will serve as the standard of truth.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study participants were individuals with DS and healthy volunteers (HVs).
Main inclusion criteria for individuals without DS
Main inclusion criteria for individuals with DS
Exclusion Criteria:
Main exclusion criteria for both groups
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Florbetaben (BAY94-9172)
300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome
The primary variables are sensitivity (percentage of DS subjects positive for cerebral beta-amyloid) and specificity (percentage of healthy volunteers negative for cerebral beta-amyloid) of brain uptake of florbetaben based on the majority read of the visual assessment by three independent blinded readers of PET images obtained 100 to 120 minutes post-injection of florbetaben.
Time frame: 100-120 min
Sensitivity Results in the Down Syndrome Age Subgroups
The majority read sensitivity (percentage of DS subjects positive for cerebral beta-amyloid by majority read) was computed for the group of DS subjects with age equal to or below the median age (DS-young) and for DS subjects with age above the median age (DS-old). The median age was 46 yrs, with 3 subjects being exactly 46 yrs old. As defined, these subjects were assigned to the DS-young group.
Time frame: 100 - 120 min
Quantitative Parameters Standard Uptake Value Ratio
The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, posterior cingulate, lateral temporal cortex, parietal cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.
Time frame: 100 - 120 min p.i.
Consistency Between Visual and Quantitative Efficacy
For a comparison of the results of the visual assessment with the quantitative assessment, descriptive Standardized Uptake Value Ratio (SUVR) statistics were computed separately for DS subjects with an abnormal/normal majority read of the PET scan (DS-PET+/DS-PET-). The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.
Time frame: 100 - 120 min
The study was conducted at two sites in the US.
| Milestone | Down Syndrome Group | Healthy Volunteer Group |
|---|---|---|
| Started | 39 | 70 |
| Completed | 39 | 70 |
| Not completed | 0 | 0 |
The primary variables are sensitivity (percentage of DS subjects positive for cerebral beta-amyloid) and specificity (percentage of healthy volunteers negative for cerebral beta-amyloid) of brain uptake of florbetaben based on the majority read of the visual assessment by three independent blinded readers of PET images obtained 100 to 120 minutes post-injection of florbetaben.
| percentage of subjects | Majority Read |
|---|---|
| Sensitivity | 46.15 (30.51 to 61.80) |
| Specificity | 100.00 (100.00 to 100.00) |
The majority read sensitivity (percentage of DS subjects positive for cerebral beta-amyloid by majority read) was computed for the group of DS subjects with age equal to or below the median age (DS-young) and for DS subjects with age above the median age (DS-old). The median age was 46 yrs, with 3 subjects being exactly 46 yrs old. As defined, these subjects were assigned to the DS-young group.
| percentage of subjects | Majority Read (DS-Young) | Majority Read (DS-Old) |
|---|---|---|
| Sensitivity Results in the Down Syndrome Age Subgroups | 23.81 (5.59 to 42.03) | 72.22 (51.53 to 92.91) |
The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, posterior cingulate, lateral temporal cortex, parietal cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.
| SUVR | Down Syndrome Group | Healthy Volunteer Group |
|---|---|---|
| frontal cortex | 1.396 ± 0.2488 | 1.146 ± 0.0749 |
| posterior cingulate | 1.525 ± 0.2549 | 1.329 ± 0.1118 |
| lateral temporal cortex | 1.350 ± 0.2265 | 1.132 ± 0.0623 |
| parietal cortex | 1.391 ± 0.2594 | 1.138 ± 0.0742 |
| cerebellum, white matter | 1.730 ± 0.2115 | 1.769 ± 0.1302 |
For a comparison of the results of the visual assessment with the quantitative assessment, descriptive Standardized Uptake Value Ratio (SUVR) statistics were computed separately for DS subjects with an abnormal/normal majority read of the PET scan (DS-PET+/DS-PET-). The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.
| SUVR | Down Syndrome PET-positive (Majority Read) | Down Syndrome PET-negative (Majority Read) | Healthy Volunteer Group |
|---|---|---|---|
| frontal cortex | 1.566 ± 0.2372 | 1.249 ± 0.1451 | 1.146 ± 0.0749 |
| posterior cingulate | 1.626 ± 0.2372 | 1.438 ± 0.2421 | 1.329 ± 0.1118 |
| lateral temporal cortex | 1.498 ± 0.2396 | 1.223 ± 0.1092 | 1.132 ± 0.0623 |
| parietal cortex | 1.557 ± 0.2567 | 1.250 ± 0.1620 | 1.138 ± 0.0742 |
| cerebellum, white matter | 1.698 ± 0.2396 | 1.758 ± 0.1856 | 1.769 ± 0.1302 |
Collected over 8 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Down Syndrome Group | — | 0/39 (0%) | 2/39 (5.1%) |
| Healthy Volunteer Group | — | 0/70 (0%) | 5/70 (7.1%) |
| Event | Down Syndrome Group | Healthy Volunteer Group |
|---|---|---|
| HeadacheNervous system disorders | 0/39 | 5/70 |
| Injection site hematomaGeneral disorders | 2/39 | 1/70 |
All Down Syndrome subjects and healthy volunteers enrolled into the study were included in the Baseline Analysis Population
| Age, Categorical(Participants) | Subjects Enrolled in Study |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 109 |
| >=65 years | 0 |
| Age, Continuous(years) | Subjects Enrolled in Study |
|---|---|
| Down Syndrome Group | 46.3 ± 4.7 |
| Healthy Volunteer Group | 27.7 ± 5.1 |
| Sex: Female, Male(Participants) | Subjects Enrolled in Study |
|---|---|
| Female | 60 |
| Male | 49 |
| Region of Enrollment(participants) | Subjects Enrolled in Study |
|---|---|
| United States | 109 |
The record gives a start of Jun 2009, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 3 years after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Florbetaben f-18